Articles tagged "Post-transplant lymphoproliferative disorder (PTLD)"

2022 American Transplant Congress
Clinical Outcomes of Solid Organ Transplant (SOT) Patients with Epstein-Barr Virus-Driven (EBV⁺) Post-Transplant Lymphoproliferative Disease (PTLD) Who Fail Rituximab Plus Chemotherapy: A Multinational, Retrospective Chart Review Study
V. Dharnidharka¹, D. Thirumalai², U. Jaeger³, W. Zhao², D. Dierickx⁴, P. Xun², P. Minga⁵, A. Sawas⁶, N. Sadetsky⁷, P. Chauvet⁸, E. Sundaram⁹, A. Barlev⁷, H. Zimmermann¹⁰, R. U. Trappe¹⁰
¹Washington University School of Medicine/St Louis Children’s Hospital, St Louis, MO, ²Atara Biotherapeutics, Thousand Oaks, CA, ³Medical University of Vienna, Vienna, Austria, ⁴Universitair Ziekenhuis Leuven, Leuven, Belgium, ⁵Niguarda Ca’ Granda Hospital, Milan, Italy, ⁶Herbert Irving Comprehensive Cancer Center, Department of Medicine, CUMC, New York, NY, ⁷Atara Biotherapeutics, South San Francisco, CA, ⁸Service des Maladies du Sang, CHU Lille, Lille, France, ⁹Nashville Biosciences, Nashville, TN, ¹⁰DIAKO Bremen, Bremen, Germany
*Purpose: EBV+ PTLD patients (pts) following SOT who fail rituximab + chemotherapy (CT) have poor outcomes with limited treatment options. Published data on clinical outcomes…
2022 American Transplant Congress
EBV+ PTLD Tumor MicroRNAs Detected in Circulating Extracellular Vesicles Are Decreased in Pediatric Transplant Recipients with EBV+ PTLD
A. Sen¹, J. Enriquez¹, M. Rao¹, M. Glass¹, Y. Balachandran¹, S. Syed¹, C. Twist¹, K. Weinberg¹, S. D. Boyd¹, D. Bernstein¹, A. Trickey¹, D. Gratzinger¹, B. Tan¹, M. G. Lapasaran¹, M. A. Robien², M. Brown³, B. Armstrong⁴, M. Sever⁴, D. Desai⁵, G. Mazariegos⁶, C. Chin⁷, T. Fishbein⁸, R. S. Venick⁹, A. Tekin¹⁰, H. Zimmermann¹¹, R. U. Trappe¹², C. O. Esquivel¹, O. M. Martinez¹, S. M. Krams¹
¹Stanford U, Palo Alto, CA, ²NIH, Bethesda, MD, ³NIAID, Bethesda, MD, ⁴Rho, Durham, NC, ⁵UT Southwestern, Dallas, TX, ⁶Pittsburgh U, Pittsburgh, PA, ⁷CCHMC, Cincinnati, OH, ⁸Georgetown U, Washington, DC, ⁹UCLA, LA, CA, ¹⁰Miami U, Miami, FL, ¹¹DIAKO Ev. Diakonie-Krankenhaus, Bremen, Germany, ¹²Charité - Universitätsmedizin, Berlin, Germany
*Purpose: Post-transplant lymphoproliferative disorder (PTLD) is a serious complication of solid organ transplantation. Predisposing factors for PTLD include primary Epstein-Barr virus (EBV) infection in children,…
2022 American Transplant Congress
Pre-Emptive Rituximab to Prevent Post Transplant Lymphoproliferative Disorder (PTLD) in Pediatric Kidney Transplant Recipients with EBV DNAemia: A Case Series from the Pediatric Nephrology Research Consortium (PNRC)
I. Ashoor¹, S. Ranabothu², S. Al-Akash³, A. Moudgil⁴, Y. Shi⁴, S. Kizilbash⁵, D. Puliyanda⁶, V. Dharnidharka⁷
¹LSU Health Sciences Center New Orleans, New Orleans, LA, ²Arkansas Children's Hospital, Little Rock, AR, ³Driscoll Children's Hospital, Corpus Christie, TX, ⁴Children's National Medical Center, Washington, DC, ⁵University of Minnesota Medical Center, Minneapolis, MN, ⁶Cedars-Sinai Medical Center, Los Angeles, CA, ⁷Washington University in St. Louis, St Louis, MO
*Purpose: The use of Rituximab (RTX) to prevent PTLD in patients with EBV DNAemia is an established strategy in hematopoietic stem cell transplants, but with…
2022 American Transplant Congress
PTLD Suspected by Visualization of Atypical Urinary Lymphocytes
J. Huidobro E¹, F. Anghileri², P. Troncoso³, A. Huete⁴, P. Downey¹
¹Nephrology, Pontificia Universidad Catolica de Chile, Santiago, Chile, ²Clinical Laboratories, Pontificia Universidad Catolica de Chile, Santiago, Chile, ³Urology, Pontificia Universidad Catolica de Chile, Santiago, Chile, ⁴Radiology, Pontificia Universidad Catolica de Chile, Santiago, Chile
*Purpose: Urinalysis has been used for the detection of acute rejection but visualization of atypical lymphocytes in the urine sediment as an early sign of…
2022 American Transplant Congress
Incidence of Posttransplant Lymphoproliferative Disorder with Belatacept Therapy versus Calcineurin Inhibitor Therapy Alone: Data from One Academic Medical Center
K. Addonizio¹, G. Petrossian¹, A. Hsiao¹, L. Teixeira¹, N. Koizumi², R. James², S. Patel³, R. Plews¹, D. Conti¹, J. Ortiz¹
¹Division of Renal and Pancreatic Transplant Services, Albany Medical Center, Albany, NY, ²George Mason University, Fairfax, VA, ³UMC Las Vegas, Las Vegas, NV
*Purpose: To compare rates of post-transplant lymphoproliferative disorder (PTLD) in patients treated with Belatacept and low-dose calcineurin inhibitors (CNIs) versus patients only treated with standard-dose…
2022 American Transplant Congress
Tabelecleucel (Tab-cel) for Solid Organ (SOT) or Allogeneic Hematopoietic Cell Transplant (HCT) Recipients with Epstein-Barr Virus-Driven Post Transplant Lymphoproliferative Disease (EBV⁺ PTLD) After Failure Of Rituximab (R) ± Chemotherapy (CT) (ALLELE)
S. Prockop¹, A. Beitinjaneh², S. Choquet³, S. Dahiya⁴, R. Dinavahi⁵, R. Farah⁶, L. Gamelin⁵, A. Joshi⁵, A. Mehta⁵, P. Nayak⁵, R. Reshef⁷, G. Satyanarayana⁸, P. Stiff⁹, W. Ye⁵, K. M. Mahadeo¹⁰
¹Boston Children's Hospital/Dana Farber Cancer Institute, Boston, MA, ²University of Miami/Jackson Memorial Hospital, Miami, FL, ³Sorbonne Université, Hôpital de la Pitié-Salpêtrière, Paris, France, ⁴University of Maryland School of Medicine, Baltimore, MD, ⁵Atara Biotherapeutics, South San Francisco, CA, ⁶UPMC Hillman Cancer Center, Pittsburgh, PA, ⁷Columbia University Medical Center, NY, NY, ⁸Ingram Cancer Center, Vanderbilt Health, Nashville, TN, ⁹Loyola University Medical Center, Chicago, IL, ¹⁰MD Anderson Cancer Center, Houston, TX
*Purpose: Tab-cel is an investigational, off-the-shelf, allogeneic EBV-specific T-cell immunotherapy for serious EBV-driven diseases, including EBV+ PTLD. Poor overall survival (OS) in patients (pts) with…
2021 American Transplant Congress
Gain of Function Mutations in Latent Membrane Protein 1 of Epstein Barr Virus are Associated with Increased Risk of Post-Transplant Lymphoproliferative Disorder
O. M. Martinez¹, S. M. Krams¹, M. Robien², M. Lapasaran¹, M. Arvedson¹, K. Weinberg¹, S. Boyd¹, B. Armstrong³, C. Twist⁴, D. Gratzinger¹, B. Tan¹, A. Trickey¹, M. Sever³, M. Brown², D. Bernstein¹, C. O. Esquivel¹
¹Stanford University Sch of Med, Stanford, CA, ²NIAID, Rockville, MD, ³Rho, Durham, NC, ⁴Roswell Park, Buffalo, NY
*Purpose: Post-transplant lymphoproliferative disorder (PTLD) remains a serious problem in the pediatric transplant population. Clinical Trials of Organ Transplantation in Children (CTOTC)-06 is a prospective…
2021 American Transplant Congress
Overall Survival by Best Overall Response with Tabelecleucel in Patients with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease After Solid Organ Transplant
S. Prockop¹, L. Gamelin², R. Dinavahi², Y. Sun², N. Guzman-Becerra², H. Parmar²
¹Memorial Sloan Kettering Cancer Center, New York, NY, ²Atara Biotherapeutics, South San Francisco, CA
*Purpose: Tabelecleucel is an investigational, off-the-shelf, allogeneic Epstein-Barr virus (EBV)-specific T-cell immunotherapy being studied in patients (pts) with serious EBV-driven diseases, including post-transplant lymphoproliferative disease…
2021 American Transplant Congress
Cancer Among Kidney Transplant Recipients More Than 20 Years After Transplantation: PTLD Remains the Most Common Cancer Type Even in the Very Long-Term
T. Schachtner, J. Fuhrmann, T. Mueller
Nephrology, University Hospital Zurich, Zurich, Switzerland
*Purpose: Due to an improved patient and kidney allograft survival, cancer is increasingly recognized as the major cause of death after kidney transplantation. Cancer risk…
2020 American Transplant Congress
Evaluation of Host Immune Responses to Epstein-Barr Virus in Lung Transplant Recipients
L. Zaffiri¹, J. E. Messinger², J. Yi², K. J. Weinhold², G. Ferrari², M. Luftig², S. M. Palmer¹
¹Pulmonary and Critical Care, Duke University, Durham, NC, ²Duke University, Durham, NC
*Purpose: After lung transplantation, Epstein-Barr virus (EBV) is a common opportunistic infection. The significance of EBV viremia following solid organ transplantation (SOT) remains unclear. Host…

1
2
3
…
9
Next Page »